EGFR and neoplasm: Bagley et al. report the results of non-prespecified interim analysis of 6 patients treated in the first 2 dose levels of an ongoing first-in-human phase 1 study with a bivalent CAR-T cell product simultaneously targeting epidermal growth factor receptor (EGFR) and IL13Rα2.6 Patients with an IDH wild-type glioblastoma that had recurred after prior radiotherapy and presence of EGFR amplification by fluorescence in situ hybridization on any prior tumor tissue specimen could be included.